What is Acelyrin Inc Annual Net Profit?

Acelyrin Inc Annual Net Profit rose 34.96% in the last year to $248.23 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

What is Acelyrin Inc Price to Earning Ratio?

Acelyrin Inc Price to Earning Ratio is -0.89, which is negative.

What is Acelyrin Inc Stock Price?

Acelyrin Inc Stock Price fell 56.09% and underperformed its sector by 63.42% in the past year.

What is Acelyrin Inc Quarterly Net profit?

Acelyrin Inc Quarterly Net profit rose 16.99% YoY to $79.03 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

What is Acelyrin Inc Debt to Equity Ratio?

Acelyrin Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Acelyrin Inc Return on Equity(ROE)?

Acelyrin Inc Return on Equity(ROE) for the last financial year was -44.54%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Acelyrin Inc Mutual Fund Holding?

Acelyrin Inc Mutual Fund Holding decreased by 8.42% in the last quarter to 28.73.

What is Acelyrin Inc Institutional Holding?

Acelyrin Inc Institutional Holding decreased by 0.01% in the last quarter to 80.34.

How is the Acelyrin Inc today?

The Acelyrin Inc today is trading in the down by 0.00% at 2.20.

How has Acelyrin Inc performed historically?

The Acelyrin Inc is currently trading down 0.00% on an intraday basis in the past week the index fell -1.35%. The index has been up 10.55% in the past quarter and fell -56.09% in the past year. You can view this in the overview section.

Acelyrin Inc XNAS: SLRN

Acelyrin Inc Live Share Price Today, Share Analysis and Chart

Name: Acelyrin Inc: Is Infosys Ltd. worth buying?
Item: Acelyrin Inc
Rating: 0.86466675
Author: Trendlyne DVM scores

Download real time

2.20 0.00 (0.00%)

69.66% Fall from 52W High

692.5K XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Acelyrin Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	221.6
PE TTM Negative PE TTM Unavailable in chosen country	-0.9
Price to Book Below industry Median Unavailable in chosen country	0.5
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	80.3
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	17
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	35
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	11.5
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-44.5
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-40.2

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

13.7 / 100

Technically Bearish

20.9 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Acelyrin Inc Stock Price Analysis

Week Price Range -1.4% 1 Week return Unavailable in chosen country	2.2 (LTP) 2.12.3 LowHigh
Month Price Range -20.6% 1 Month return Unavailable in chosen country	2.2 (LTP) 22.9 LowHigh
52 Week Price Range -56.1% 1 Year return Unavailable in chosen country	2.2 (LTP) 1.87.2 LowHigh

View full Share Price History

Acelyrin Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Acelyrin Inc Stock Analysis

Acelyrin Inc stock analysis with key metrics, changes, and trends.

Acelyrin Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$248.23 M	34.96%	positive	Annual Net Profit rose 34.96% in the last year to $248.23 M. Its sector's average net profit growth for the last fiscal year was -30.36%.
Price to Earning Ratio	-0.89	-	negative	Price to Earning Ratio is -0.89, which is negative.
Stock Price	$2.20	-56.09%	negative	Stock Price fell 56.09% and underperformed its sector by 63.42% in the past year.
Quarterly Net profit	$79.03 M	16.99%	positive	Quarterly Net profit rose 16.99% YoY to $79.03 M. Its sector's average net profit growth YoY for the quarter was -48.37%.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-44.54 %	-44.54%	negative	Return on Equity(ROE) for the last financial year was -44.54%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	28.73 %	-8.42%	negative	Mutual Fund Holding decreased by 8.42% in the last quarter to 28.73.
Institutional Holding	80.34 %	-0.01%	negative	Institutional Holding decreased by 0.01% in the last quarter to 80.34.

VIEW LESS

Loading data..

Acelyrin Inc - Company Profile

What does Acelyrin Inc do?

Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Gross Remuneration

2024

Gross Remuneration

Year

Acelyrin Inc Live Share Price Today, Share Analysis and Chart

69.66% Fall from 52W High

Acelyrin Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Acelyrin Inc Stock Price Analysis

Week Price Range

Month Price Range

52 Week Price Range

Acelyrin Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Acelyrin Inc Stock Analysis

Acelyrin Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 34.96% in the last year to $248.23 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio is -0.89, which is negative.

Stock Price fell 56.09% and underperformed its sector by 63.42% in the past year.

Quarterly Net profit rose 16.99% YoY to $79.03 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -44.54%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 8.42% in the last quarter to 28.73.

Institutional Holding decreased by 0.01% in the last quarter to 80.34.

Acelyrin Inc - Company Profile

What does Acelyrin Inc do?

Acelyrin Inc Management structure

Mr. Gil M. Labrucherie

Chief Business Officer, Chief Financial Officer and Principal Accounting Officer

Ms. Mina Kim

Director; Chief Executive Officer; Principal Financial Officer and Principal Accounting officer

Dr. Shao-Lee Lin, M.D.,PhD

Founder, Chief Executive Officer and Director

Mr. Ron Oyston

Chief People Officer

Mr. Shephard Mpofu, M.D.

Chief Medical Officer

Ms. Sanam Pangali

Chief Legal Officer and Head of People

Acelyrin Inc Board of directors

Ms. Mina Kim

Director; Chief Executive Officer; Principal Finan

Dr. Shao-Lee Lin, M.D.,PhD

Founder, Chief Executive Officer and Director

Dr. Beth C. Seidenberg,M.D.

Independent Director

Mr. Bruce C. Cozadd

Chairman of the Board

Mr. Patrick C. Machado, J.D.

Independent Director

Dr. Alan B. Colowick, M.D.,M.P.H.

Independent Director

Acelyrin Inc FAQ

How is Acelyrin Inc today?

Acelyrin Inc today is trading in the red, and is down by 0.00% at 2.20.

How has Acelyrin Inc performed historically?

Acelyrin Inc is currently trading down 0.00% on an intraday basis. In the past week the stock fell -1.35%. stock has been up 10.55% in the past quarter and fell -56.09% in the past year. You can view this in the overview section.